X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES LUPIN LTD JUBILANT LIFE SCIENCES/
LUPIN LTD
 
P/E (TTM) x 27.4 20.3 135.0% View Chart
P/BV x 5.6 2.8 204.5% View Chart
Dividend Yield % 0.3 0.9 35.5%  

Financials

 JUBILANT LIFE SCIENCES   LUPIN LTD
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
LUPIN LTD
Mar-17
JUBILANT LIFE SCIENCES/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1871,750 10.7%   
Low Rs651,384 4.7%   
Sales per share (Unadj.) Rs364.3387.4 94.0%  
Earnings per share (Unadj.) Rs6.856.6 12.1%  
Cash flow per share (Unadj.) Rs24.576.8 31.9%  
Dividends per share (Unadj.) Rs3.007.50 40.0%  
Dividend yield (eoy) %2.40.5 497.6%  
Book value per share (Unadj.) Rs164.9298.9 55.2%  
Shares outstanding (eoy) m159.28451.58 35.3%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x0.34.0 8.5%   
Avg P/E ratio x18.427.7 66.5%  
P/CF ratio (eoy) x5.120.4 25.2%  
Price / Book Value ratio x0.85.2 14.6%  
Dividend payout %43.813.2 330.9%   
Avg Mkt Cap Rs m20,061707,513 2.8%   
No. of employees `0006.216.8 36.8%   
Total wages/salary Rs m11,05228,495 38.8%   
Avg. sales/employee Rs Th9,383.010,418.3 90.1%   
Avg. wages/employee Rs Th1,786.91,697.0 105.3%   
Avg. net profit/employee Rs Th176.31,523.0 11.6%   
INCOME DATA
Net Sales Rs m58,034174,943 33.2%  
Other income Rs m1911,065 17.9%   
Total revenues Rs m58,224176,008 33.1%   
Gross profit Rs m5,78644,931 12.9%  
Depreciation Rs m2,8129,122 30.8%   
Interest Rs m3,2371,525 212.2%   
Profit before tax Rs m-7235,349 -0.2%   
Minority Interest Rs m-286-72 398.9%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m2,1450-   
Tax Rs m6969,785 7.1%   
Profit after tax Rs m1,09025,575 4.3%  
Gross profit margin %10.025.7 38.8%  
Effective tax rate %-965.927.7 -3,489.3%   
Net profit margin %1.914.6 12.9%  
BALANCE SHEET DATA
Current assets Rs m29,280119,542 24.5%   
Current liabilities Rs m38,91261,206 63.6%   
Net working cap to sales %-16.633.3 -49.8%  
Current ratio x0.82.0 38.5%  
Inventory Days Days8476 111.0%  
Debtors Days Days5190 56.4%  
Net fixed assets Rs m55,712131,660 42.3%   
Share capital Rs m155903 17.1%   
"Free" reserves Rs m20,968134,073 15.6%   
Net worth Rs m26,265134,976 19.5%   
Long term debt Rs m17,16956,478 30.4%   
Total assets Rs m88,606266,073 33.3%  
Interest coverage x1.024.2 4.0%   
Debt to equity ratio x0.70.4 156.2%  
Sales to assets ratio x0.70.7 99.6%   
Return on assets %4.910.2 48.0%  
Return on equity %4.218.9 21.9%  
Return on capital %11.619.3 60.0%  
Exports to sales %37.80-   
Imports to sales %16.50-   
Exports (fob) Rs m21,933NA-   
Imports (cif) Rs m9,567NA-   
Fx inflow Rs m22,00481,885 26.9%   
Fx outflow Rs m11,74921,506 54.6%   
Net fx Rs m10,25560,378 17.0%   
CASH FLOW
From Operations Rs m8,02641,148 19.5%  
From Investments Rs m-1,744-25,287 6.9%  
From Financial Activity Rs m-4,4474,332 -102.7%  
Net Cashflow Rs m1,83420,193 9.1%  

Share Holding

Indian Promoters % 45.6 46.6 97.9%  
Foreign collaborators % 3.5 0.2 1,750.0%  
Indian inst/Mut Fund % 8.7 11.3 77.0%  
FIIs % 21.2 31.9 66.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 10.1 208.9%  
Shareholders   23,815 98,259 24.2%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   SUVEN LIFE  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  SUN PHARMA  

Compare JUBILANT LIFE SCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Feb 16, 2018 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 8-QTR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS